Top-Rated StocksTop-RatedNASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $18.57 +0.61 (+3.40%) Closing price 04:00 PM EasternExtended Trading$18.58 +0.00 (+0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dianthus Therapeutics Stock (NASDAQ:DNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$17.37▼$18.7450-Day Range$14.86▼$21.8752-Week Range$13.37▼$32.27Volume160,091 shsAverage Volume275,776 shsMarket Capitalization$597.21 millionP/E RatioN/ADividend YieldN/APrice Target$53.00Consensus RatingBuy Company OverviewDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Read More… Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 838th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDianthus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.57% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 2.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.57% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 2.74%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News SentimentN/A News SentimentDianthus Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dianthus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.15% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Stock News HeadlinesDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comDianthus Therapeutics appoints new board memberMay 24, 2025 | investing.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 5, 2025 | Crypto 101 Media (Ad)Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22, 2025 | globenewswire.com4DNTH : Breaking Down Dianthus Therapeutics: 5 Analysts Share Their ViewsMay 13, 2025 | benzinga.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 12, 2025 | globenewswire.comDianthus Therapeutics completes enrollment for MaGic trialMay 6, 2025 | investing.comDianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in SeptemberMay 5, 2025 | globenewswire.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $21.80 on January 1st, 2025. Since then, DNTH shares have decreased by 14.8% and is now trading at $18.57. View the best growth stocks for 2025 here. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.04. The firm earned $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 21.68% and a negative net margin of 1,250.32%. Who are Dianthus Therapeutics' major shareholders? Top institutional investors of Dianthus Therapeutics include RA Capital Management L.P. (8.92%), Octagon Capital Advisors LP (7.29%), Vestal Point Capital LP (5.29%) and Vanguard Group Inc. (3.45%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/12/2025Today6/05/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$53.00 High Stock Price Target$84.00 Low Stock Price Target$36.00 Potential Upside/Downside+185.4%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.56 million Net Margins-1,250.32% Pretax Margin-1,250.32% Return on Equity-21.68% Return on Assets-20.88% Debt Debt-to-Equity RatioN/A Current Ratio18.30 Quick Ratio18.30 Sales & Book Value Annual Sales$6.52 million Price / Sales91.54 Cash FlowN/A Price / Cash FlowN/A Book Value$11.40 per share Price / Book1.63Miscellaneous Outstanding Shares32,160,000Free Float24,696,000Market Cap$597.21 million OptionableOptionable Beta1.48 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:DNTH) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.